Sage Therapeutics, Inc. (SAGE) Stake Increased by TD Asset Management Inc.
TD Asset Management Inc. boosted its position in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 21.5% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 73,030 shares of the biopharmaceutical company’s stock after buying an additional 12,921 shares during the period. TD Asset Management Inc. owned approximately 0.20% of Sage Therapeutics worth $5,190,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Norges Bank bought a new stake in Sage Therapeutics during the fourth quarter valued at $12,452,000. Russell Investments Group Ltd. bought a new stake in Sage Therapeutics during the fourth quarter valued at $538,000. Guggenheim Capital LLC increased its stake in Sage Therapeutics by 32.2% in the fourth quarter. Guggenheim Capital LLC now owns 80,010 shares of the biopharmaceutical company’s stock valued at $4,085,000 after buying an additional 19,501 shares during the last quarter. Jana Partners LLC bought a new stake in Sage Therapeutics during the third quarter valued at $5,117,000. Finally, Parametrica Management Ltd bought a new stake in Sage Therapeutics during the first quarter valued at $398,000.
Shares of Sage Therapeutics, Inc. (NASDAQ SAGE) traded up 3.32% during trading on Friday, reaching $79.71. The company had a trading volume of 706,776 shares. Sage Therapeutics, Inc. has a 1-year low of $26.55 and a 1-year high of $80.30. The stock’s market capitalization is $2.98 billion. The company’s 50 day moving average is $70.20 and its 200-day moving average is $61.67.
Sage Therapeutics (NASDAQ:SAGE) last issued its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.61) by $0.09. On average, equities research analysts anticipate that Sage Therapeutics, Inc. will post ($6.70) earnings per share for the current year.
Several analysts recently weighed in on SAGE shares. Needham & Company LLC started coverage on Sage Therapeutics in a research note on Monday, May 15th. They issued a “buy” rating and a $82.00 price target on the stock. Bank of America Corporation started coverage on Sage Therapeutics in a research note on Friday, May 12th. They issued a “buy” rating and a $85.00 price target on the stock. Canaccord Genuity restated a “buy” rating and issued a $110.00 price target on shares of Sage Therapeutics in a research note on Wednesday, May 10th. J P Morgan Chase & Co reaffirmed a “buy” rating and issued a $83.00 price objective on shares of Sage Therapeutics in a research report on Monday, April 3rd. Finally, ValuEngine raised Sage Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Four analysts have rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the company. Sage Therapeutics presently has an average rating of “Buy” and a consensus target price of $78.92.
Sage Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.